To Our Shareholders
and Investors

• October 11, 2024

  R & D
  VILTEPSO® (viltolarsen) injection: Phase II study (Galactic53 trial) Data Published in Scientific Reports PDF150 KB
• September 24, 2024

  Pharmaceuticals
  Johnson & Johnson Obtains Approval for YUVANCI ® Combination Tablet for the Treatment of Pulmonary Arterial Hypertension PDF159 KB
• September 18, 2024

  R & D
  Nippon Shinyaku and Capricor Therapeutics Execute Letter of Intent for Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Europe PDF147 KB
• September 06, 2024

  R & D
  FDA Grants Rare Pediatric Disease Designation to NS-050/NCNP-03 for the Treatment of Duchenne Muscular Dystrophy PDF261 KB

Upcoming Events

• November 15, 2024

  IR Meeting(Q2/FY2024)

• November 13, 2024

  FY2024 2nd Qtr results announcement

• August 07, 2024
  Conference Call(Q1/FY2024) PDF3.4 MB
• August 07, 2024
  FY2024 1st Qtr results announcement PDF702 KB
• May 28, 2024
  7th Five-Year Medium-Term Management Plan Meeting PDF8.6 MB